DALIPAL HLDG(01921) spent approximately 1.4185 million Hong Kong dollars to repurchase 454,000 shares on June 10th.
Dali Group Holdings (01921) announced the repurchase of 454,000 shares for approximately HK$1.4185 million on June 10, 2026.
DALIPAL HLDG (01921) announced that on June 10, 2026, it spent approximately 1.4185 million Hong Kong dollars to repurchase 454,000 shares.
Related Articles
SIPAI HEALTH (00314) repurchased 200,000 shares at a cost of approximately HKD 240,200 on June 10th.
ALPHAMAB-B(09966): The phase III clinical study of Anituximab (KN026) as first-line treatment for HER2-positive advanced breast cancer has reached the primary endpoint.
CSPC PHARMA (01093): The phase III study of the combination of Anetumab ravtansine (KN026) with albumin-bound paclitaxel (HB1801) for first-line treatment for HER2-positive advanced breast cancer has reached its primary endpoint.
SIPAI HEALTH (00314) repurchased 200,000 shares at a cost of approximately HKD 240,200 on June 10th.
ALPHAMAB-B(09966): The phase III clinical study of Anituximab (KN026) as first-line treatment for HER2-positive advanced breast cancer has reached the primary endpoint.
CSPC PHARMA (01093): The phase III study of the combination of Anetumab ravtansine (KN026) with albumin-bound paclitaxel (HB1801) for first-line treatment for HER2-positive advanced breast cancer has reached its primary endpoint.
RECOMMEND
